Plaque Psoriasis

These data highlight several key points about COPD and its prevalence, risk, and incidence among plaque psoriasis patients.

In this clinical quiz, you will test your knowledge of psoriasis guidelines, with special focus on important clinical questions related to management of psoriasis and recent evidence-based recommendations.

This summary of major dermatology news covered in June highlights stories such as late-breaking data at RAD 2024, recent interviews, and recent FDA news.

The case series highlighted here was limited due to smaller numbers of participants, necessitating additional real-world data on bimekizumab for psoriasis.

These real-world findings on tildrakizumab’s use among patients with moderate-to-severe plaque psoriasis highlight the drug’s efficacy regarding high burden symptoms.

In this analysis, disparities associated with race, old age, socioeconomic differences, and rural residence were highlighted as examples.

These findings made comparisons between clinical outcomes of interclass and intraclass switching of biologic treatments among individuals with psoriasis.

These data were identified to expand upon existing information regarding treatment options for facial psoriasis and/or genital psoriasis.

These data suggest that quality of life, assessed by DLQI, may be implemented in determining treatment efficacy among patients with psoriasis.

These data, resulting from a post-hoc analysis, highlighted the musculoskeletal, skin, and nail outcomes among patients with psoriasis and PsA.

This analysis among Japanese patients highlights the potential of apremilast for psoriasis patients not responding to topical therapy who may have limited systemic treatment options.

A meta-analysis shows hand eczema has a moderate-to-severe impact on quality of life and anxiety.

In this systematic review and meta-analysis, the clinical efficacy of glucagon-like peptide 1 receptor agonists was evaluated.

These data highlight rates of biologic treatment discontinuation in younger adult patients versus elderly patients, with comparisons drawn between IL-23 inhibitors and IL-17 inhibitors as well.

These data do not support the idea that interferon-beta works as a trigger for psoriasis, though it may have a different influence on psoriasis among those with MS versus those without MS.

These data resulted from a new meta-analysis in which biologic therapies were shown to be less effective among psoriasis patients with clinical characteristics such as age and BMI.

These data may require large-scale studies to duplicate the findings, evaluating individuals with psoriasis who had PPM for IE antibiotic prophylaxis.

These data suggest that those with psoriasis maintain an innate psychological vulnerability, indicating the necessity of addressing mental well-being in the disease’s management.

These multicenter, retrospective data highlight the use of guselkumab after discontinuing ustekinumab treatment up to 156 weeks of use.

A new study found a negative correlation between salivary rates and disease severity for patients with psoriasis.

A new study found patients with psoriasis and depression have increased levels of C-reaction proteins and the erythrocyte sedimentation rate.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

These findings highlight potential drawbacks of treating psoriasis with phototherapy versus anti-TNFα therapy, though additional research is needed.

This retrospective, systematic review highlighted the lack of studies specifically addressing the needs of patients with inverse psoriasis.

These data on genetic correlations allow for new genetic evidence connecting psoriasis and patients’ socioeconomic status.

These data highlight the effects of psoriasis on the mental health of adolescents in Denmark.

In this analysis of independent risk factors for developing PsA from psoriasis, the use of MRI to detect such factors was noted as helpful for investigators.

These data highlighted patient-reported and clinical outcomes among those with psoriasis, with data drawn retrospectively from Germany, Poland, Czech Republic, Japan, and Canada.

Biologic therapy for psoriasis showed no significant impact on cardiovascular risk factors over one year in a retrospective study from Australia.

These results may support clinical decision-making for psoriasis and nail psoriasis management and may allow future real-world studies to further understand the nature of this skin disease.